Vaccines Access

ACIP Recommendation by Product and Age

Routine versus risk-based versus shared clinical decision. Coverage design is the demand switch. 2026 childhood-schedule edits are stayed.

Influenza (seasonal)

Population:
Everyone 6 months+
ACIP posture:
Routine annual
Why it matters:
Coverage benchmark. 2025-26 adult uptake 46.5% (NIS-FRVM).

COVID (seasonal)

Population:
Adults; narrower than pandemic
ACIP posture:
Seasonal; age and risk rules have tightened
Why it matters:
Coverage 17.5% of adults 18+ in 2025-26. Recommendation design is the demand switch.

RSV vaccines (Arexvy, Abrysvo, mRESVIA)

Population:
75+; 50-74 at increased risk
ACIP posture:
Single dose, not annual. No product preference.
Why it matters:
Arexvy sales were £1,238m in 2023, £590m in 2024 and £593m in 2025. GSK cites a more limited ACIP recommendation for ages 60 to 74 and channel inventory consumption.

Beyfortus (nirsevimab)

Population:
Infants entering first RSV season
ACIP posture:
Routine infant prevention
Why it matters:
Competes with maternal Abrysvo. Sanofi said Beyfortus was not hit by the 2026 childhood-schedule edit.

Enflonsia (clesrovimab)

Population:
Infants entering first RSV season
ACIP posture:
FDA approved Jun 2025; ACIP vote is in the stayed set
Why it matters:
CRS notes the June 2025 infant-RSV vote may not currently sit on the CDC schedule. Coverage is unsettled.

Abrysvo (maternal)

Population:
Pregnancy, 32-36 weeks
ACIP posture:
Maternal indication
Why it matters:
Only RSV vaccine with a pregnancy label. Not split out in Pfizer's product table.

Shingrix

Population:
Adults 50+
ACIP posture:
Routine
Why it matters:
IRA $0 Part D copay. US immunization 44%; ex-US is now 66% of GSK sales.

Prevnar family / Capvaxive / Vaxneuvance

Population:
Pediatric routine; adult pneumococcal by age and risk
ACIP posture:
Routine pediatric; adult share fight
Why it matters:
VFC catalog is the public-sector price. Adult is pharmacy and Part D.

Gardasil 9

Population:
9-26 routine; 27-45 shared clinical decision
ACIP posture:
Routine through 26
Why it matters:
Shared decision-making is a coverage binary. China destock is a tender risk, not an ACIP risk.

CDC Posted Immunization Schedule, July 2025

The child and adult tables CDC currently labels as live under the 16 Mar 2026 stay. Not uptake. Not a stayed ACIP vote. Enflonsia's June 2025 vote is omitted on purpose.

Hepatitis B

CDC posted posture:
Routine childhood series. Adult table: 2, 3, or 4 doses depending on vaccine
Ages on the posted tables:
Birth dose, then 1 to 2 months and 6 to 18 months on the child table
Roster P&L:
HEPLISAV-B is the 2-dose adult product in the Sanofi-Dynavax deal. Pediatric HepB sits in combination books.

Rotavirus

CDC posted posture:
Routine infant
Ages on the posted tables:
2 and 4 months (RV1) or 2, 4, and 6 months (RV5)
Roster P&L:
Merck RotaTeq $673M in 2025. GSK Rotarix is inside established and Gavi volume.

DTaP / Tdap

CDC posted posture:
Routine childhood plus adolescent booster
Ages on the posted tables:
DTaP on the infant table (2, 4, 6, 15 months). Tdap: 1 dose at 11 to 12 years (CDC child notes)
Roster P&L:
Sanofi PPH and GSK established. Not a single SKU P&L.

Hib

CDC posted posture:
Routine infant
Ages on the posted tables:
2, 4, then 12 to 15 months (third or fourth dose per notes)
Roster P&L:
Inside Sanofi PPH.

Pneumococcal conjugate

CDC posted posture:
Routine pediatric. Adult 50+ if never received a PCV (MMWR 2025 adult schedule)
Ages on the posted tables:
Infant 2, 4, 6, and 12 to 15 months (PCV15 or PCV20) on the child table. Adult table: see notes; MMWR 2025: universal at 50+ if no prior PCV15/20/21
Roster P&L:
Pfizer Prevnar family $6.494B. Merck Vaxneuvance and Capvaxive.

IPV

CDC posted posture:
Routine childhood
Ages on the posted tables:
2, 4, 6 to 18 months, and 4 to 6 years
Roster P&L:
Inside Sanofi PPH.

Influenza

CDC posted posture:
Routine annual from 6 months
Ages on the posted tables:
1 or 2 doses annually by age and prior doses. Adult 65+ prefers HD, recombinant, or adjuvanted
Roster P&L:
Sanofi flu/COVID bundle (unsplit). CSL Seqirus. GSK influenza £303M.

COVID-19

CDC posted posture:
Seasonal; see notes
Ages on the posted tables:
Posted child and adult tables point to notes, not a fixed annual age band
Roster P&L:
Pfizer Comirnaty and Moderna Spikevax. Recommendation design is the demand switch. This row is the posted schedule, not uptake.

MMR and varicella

CDC posted posture:
Routine two-dose
Ages on the posted tables:
First dose 12 to 15 months. Second dose 4 to 6 years
Roster P&L:
Merck ProQuad / M-M-R II / Varivax $2.451B.

Hepatitis A

CDC posted posture:
Routine childhood two-dose
Ages on the posted tables:
12 to 23 months
Roster P&L:
Tender and travel adjacency. Not a named 2025 franchise line here.

HPV

CDC posted posture:
Routine adolescent; adult catch-up through 26; 27 to 45 shared clinical decision
Ages on the posted tables:
CDC child notes: routinely recommended at 11 to 12 years (can start at 9); catch-up through 18. Adult table: 19 to 26 (2 or 3 doses); 27 to 45 shared clinical decision
Roster P&L:
Merck Gardasil. Shared decision-making is a coverage binary.

MenACWY

CDC posted posture:
Routine adolescent two-dose
Ages on the posted tables:
CDC child notes: 2-dose series at 11 to 12 years and 16 years
Roster P&L:
GSK Menveo / Penmenvy. Sanofi MenQuadfi sits inside the unsplit meningitis/travel/endemic bundle.

MenB

CDC posted posture:
Shared clinical decision at 16 to 23, not a routine series
Ages on the posted tables:
CDC child notes: healthy adolescents 16 to 23 (preferred 16 to 18), 2 doses 6 months apart based on shared clinical decision-making. Increased-risk: 3-dose series
Roster P&L:
GSK Bexsero. Shared decision is the demand switch, not a second COVID.

RSV infant (nirsevimab)

CDC posted posture:
Routine infant prevention on the child table
Ages on the posted tables:
1 dose depending on maternal RSV vaccination status, with 8 to 19 months notes
Roster P&L:
Sanofi/AZ Beyfortus. Merck Enflonsia is FDA-approved; its June 2025 ACIP vote, which the CDC Director adopted (Merck 10-K, 24 Feb 2026), is in the set stayed on 16 Mar 2026 and is not treated as coverage here.

RSV vaccine (Abrysvo, adults)

CDC posted posture:
Maternal seasonal; adult 75+ and 50 to 74 at increased risk
Ages on the posted tables:
Child table: seasonal in pregnancy. Adult table: 75+ and 50 to 74 (see notes). Single dose, not annual
Roster P&L:
Pfizer Abrysvo. GSK Arexvy and Moderna mRESVIA share the adult row. The 27 Apr 2026 adult-page amendment added the April 2025 RSV language as adopted by HHS.

Shingles (RZV)

CDC posted posture:
Routine adult 50+
Ages on the posted tables:
2 doses at 50 to 64 and 65+
Roster P&L:
GSK Shingrix. No 2026 US commercial competitor.

CDC VFC Catalog Prices, April 2026

What the US public sector pays versus private list. Gardasil $275, Prevnar 20 $200, Beyfortus $444 at CDC cost.

CDC cost / dosePrivate sector / dose
Beyfortus 50mg / 100mg (Sanofi)$443.78$595.06
Enflonsia (Merck)$422.04$556.00
Gardasil 9 (Merck)$275.01$328.24
Abrysvo (Pfizer)$240.04$319.07
Prevnar 20 (Pfizer)$200.13$299.25
ProQuad (Merck)$194.95$286.17
Jynneos (Bavarian Nordic)$232.71$264.56
Bexsero (GSK)$159.12$251.31
Vaxneuvance (Merck)$184.19$239.87
MenQuadfi (Sanofi)$117.77$177.11
Vaxelis (Merck)$108.72$167.36
Pentacel (Sanofi)$78.39$130.53
RotaTeq (Merck)$87.35$101.99
M-M-R II (Merck)$26.93$95.74
$0$200$400$600

WHO 2024 Dose Volume vs Value

7.2 billion doses and $66 billion of value. DCVMN and SII win volume. IFPMA wins the P&L. UNICEF and self-procuring MICs buy most doses.

2024 global market
7.2B doses
$66B financial value. Volume +7%, value -13% vs 2023 on COVID decline.
DCVMN share of doses
~2/3
Developing-country manufacturers, led by Serum Institute. Not the USD P&L.
IFPMA share of value
~80%
GSK, Merck, Pfizer, Sanofi, Moderna. Same order as 2023.
R21 Gavi price
$2.99
Nov 2025 SII/Gavi/UNICEF deal. Contrast with VFC Gardasil at $275.
Self-procuring MICs
44%
Share of 2024 doses bought
UNICEF pooled (incl. Gavi)
37%
Share of 2024 doses bought

BARDA and SNS: Freeze-Dried Jynneos

Option exercises, not pharmacy demand. $156.8M bulk in 2024 through $97M remaining freeze-dried doses for 2027.

27 Sep 2017
DealBavarian Nordic

BARDA awards Bavarian Nordic a ten-year contract for freeze-dried smallpox vaccine, potential value above $539M

Initial award of $100M for bulk manufacturing and storage; initial options include $299M for filling and freeze-drying. The vaccine was then named IMVAMUNE. Contract HHSO100201700019C.

Jun-Jul 2022
ProcurementBavarian Nordic

BARDA orders 5.5M liquid-frozen Jynneos doses for the mpox outbreak: 500,000 on 10 Jun, 2.5M on 1 Jul and 2.5M on 15 Jul 2022

Filled from bulk already made under earlier BARDA contracts, most of which was to be converted into about 13 million freeze-dried doses. Bavarian Nordic said in Aug 2023 that replenishing the bulk was necessary to deliver the freeze-dried version.

8 Aug 2024
DealBavarian Nordic

BARDA orders $156.8M of Jynneos bulk

$139.7M of bulk, manufactured and invoiced in 2024, partly replenishes inventory used in the 2022 mpox response. About $17M covers services in 2025-2027, including storage of vaccine doses in the US.

24 Sep 2024
DealBavarian Nordic

Additional BARDA order of $63M for bulk and freeze-dried doses

Bulk, planned for 2025, further replenishes the 2022 mpox inventory. The order also supports manufacturing of 1 million freeze-dried doses, delivered in 2026.

31 Mar 2025
ApprovalBavarian Nordic

FDA approves a freeze-dried, two-vial presentation of Jynneos

Supplement to the Jynneos BLA, for adults 18 and older. Bavarian Nordic cites advantages in transportation, storage conditions and shelf life for long-term stockpiling.

6 May 2025
DealBavarian Nordic

BARDA exercises $143.6M of options for 2026 delivery

Covers converting bulk into freeze-dried doses, plus supplemental payments for all doses under the freeze-dried contract, triggered by the demonstration of an extended shelf-life. Deliveries planned for 2026.

11 May 2026
DealBavarian Nordic

BARDA exercises $97M more of options, securing the remaining doses of the original 11.5M-dose freeze-dried order

Mostly bulk, to replace bulk consumed for liquid-frozen doses in the 2022-23 outbreak, invoiced in 2026. Freeze-dried doses are manufactured and delivered in 2027. The company raised 2026 Public Preparedness revenue guidance to DKK 2.3B-2.5B.

US Vaccine Policy Timeline, 2025 to 2026

ACIP reconstitution, the 17-to-11 childhood-schedule rewrite, lower US vaccine sales in Q1 2026, and the March 2026 stay. Live litigation.

9 Jun 2025
ACIPHHS / CDC

HHS Secretary terminates all 17 ACIP members; new members are appointed on 11 Jun 2025

Further members were appointed on 11 Sep 2025 and 13 Jan 2026. The 16 Mar 2026 court order below stayed the appointments of 13 of them and all votes taken by that ACIP.

5 Jan 2026
ACIPCDC / HHS

HHS memo revises the childhood immunization schedule: routine recommendations fall from 17 to 11

ACIP was not involved in the change. Some recommendations were limited to high-risk groups and others moved to shared clinical decision-making.

Apr-May 2026
ProcurementSanofi / Pfizer / Merck

Sanofi, Pfizer and Merck report lower US sales for several vaccines in Q1 2026

Sanofi: US meningitis, travel and endemic vaccines down 17.5%. Pfizer: US Comirnaty down 43% and US Prevnar family down 10%, with lower Comirnaty utilization attributed primarily to a narrower recommendation. Merck: lower US Gardasil sales, primarily from unfavorable public-sector purchasing patterns.

16 Mar 2026
ACIPAAP v. Kennedy

Massachusetts district court stays the January 2026 childhood-schedule memo, 13 ACIP appointments and the votes taken by that ACIP

Preliminary relief under 5 U.S.C. 705, not a final judgment. The government filed a notice of appeal on 29 Apr 2026.

5 Aug 2026
LeadershipSenate / CDC

Senate confirms Erica Schwartz as CDC director, 51 to 44

Roll call vote EX. 220. Cloture on the nomination was agreed 51 to 43 (EX. 219) the same day.

8 Sep 2026
LeadershipHHS / FDA

HHS names Karim Mikhail CBER director and Michael Davis CDER director

FDA lists Mikhail as CBER director, Davis as CDER director and Kyle Diamantas as Acting Commissioner. Not confirmed in a primary source as of 2026-11-01: the 8 Sep 2026 announcement date and that both had been serving as acting directors.

24 Sep 2026
LeadershipSenate HELP

Senate HELP Committee holds confirmation hearing on Heidi Overton for FDA commissioner

A hearing, not a confirmation vote. The nominee was introduced by Senator Hagerty. FDA lists Kyle Diamantas as Acting Commissioner.

IRA Part D Zero Cost-Share Uptake

10.3 million Part D enrollees vaccinated at $0 in 2023 versus 3.4 million in 2021. Shingles +42%. RSV was a launch-year print, not an annual franchise.

Metric2021 (cost-sharing)2023 ($0 copay)
Part D enrollees vaccinated3.4 million10.3 million (~20% of Part D)
Enrollee OOP for ACIP adult vaccines$234 million$0 (>$400 million saved)
Shingles recipients2.7 million3.9 million (+42%)
RSV recipientsNot yet licensed6.5 million (launch year)
Share of 2023 mix (ASPE)n/aRSV 63%, shingles 38%, Tdap/Td ~15%

China Gardasil Destock

International sales fell from $6.158B to $2.592B. WHO: China was half of 2024 HPV financial value, all private sector.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Vaccines Access: Market Data | Sterling